背景:分子靶向药物(MTA)的出现改变了激素受体阳性(HR)的治疗前景,人表皮生长因子2阴性(HER2-)晚期乳腺癌(ABC)/转移性乳腺癌(MBC)。各种指南推荐分子靶向治疗作为HR+/HER2-ABC/MBC的一线治疗。然而,MTA治疗后疾病进展后的后续治疗仍未确定.这项研究评估了不同类型的MTA对此类患者的适用性。
方法:在这项回顾性研究中,56例接受palbociclib治疗的HR+/HER2-ABC/MBC患者的电子健康记录,abemaciclib,对我们机构2014年4月至2021年6月期间的依维莫司进行了分析。
结果:总体而言,39、14和35方案与帕博西尼,abemaciclib,和依维莫司,分别,被使用。共有3例和53例患者在绝经前和绝经后,分别。MTA包括在第1-11行治疗中。三种MTA之间的失效时间(TTF)显着不同。相比之下,在有/未使用mTOR抑制剂的50种治疗方案的患者和有/未使用CDK4/6抑制剂的35种治疗方案的患者之间,TTF无显著差异.
结论:依次使用不同类别的MTA并不影响另一种MTA的TTF。因此,mTOR抑制剂+依西美坦是CDK4/6抑制剂+激素治疗后施用的有利治疗选择。CDK4/6抑制剂+激素疗法也适用于以前用mTOR抑制剂+依西美坦治疗的患者。尽管采用了回顾性和单中心研究设计,这些发现为临床实践中的治疗选择提供了有用的信息.
BACKGROUND: The emergence of molecularly targeted agents (MTAs) has altered the treatment landscape for hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) /metastatic breast cancer (MBC). Multiple guidelines recommend molecularly targeted therapy as first-line treatment for HR+/HER2- ABC/MBC. However, optimal treatment for disease progression during MTA therapy remains undetermined. This study evaluated the suitability of different MTA types for this patient subgroup.
METHODS: In this retrospective study, we analyzed the electronic health records of 56 patients with HR+/HER2- ABC/MBC receiving treatment with palbociclib, abemaciclib, or everolimus in our center between April 2014 and June 2021.
RESULTS: Overall, 39, 14, and 35 regimens using palbociclib, abemaciclib, and everolimus, respectively, were identified. Three and 53 patients were premenopausal and postmenopausal, respectively. MTAs were included in the 1st-11th lines of treatment. Time to failure (TTF) was significantly different among the three MTAs. In contrast, TTF did not significantly differ among the 50 regimens that included CDK4/6 inhibitors, with/without prior mTOR inhibitor use, and the 35 regimens that included mTOR inhibitors, with/without prior CDK4/6 inhibitor use.
CONCLUSIONS: The sequential use of different MTA classes did not affect the TTF of another MTA. mTOR inhibitor + exemestane is a favorable treatment option after CDK4/6 inhibitor + hormone therapy, and CDK4/6 inhibitor + hormone therapy is suitable for patients previously treated with mTOR inhibitor + exemestane. Although this study was retrospective and conducted at a single center, the present findings are useful for treatment selection in clinical practice.